Determinants in early life for asthma development

A reliable screening test in newborns for the subsequent development of bronchial asthma (BA) has not been found yet. This is mainly due to the complexity of BA, being made up by different types and underlying mechanisms. In different studies, a number of risk factors for BA have been identified. These include a positive family history of BA, passive smoking (also during pregnancy), prematurity (including pulmonary infections, RDS and BPD), early viral respiratory infections (such as RSV-bronchiolitis), male gender, early lung function abnormalities and atopic constitution. The major risk factor for persistent BA is an underlying allergic constitution. Therefore, early symptoms and markers of allergy (i.e. The Allergic March) and a positive family history for allergy should be considered as important risk factors for the development of BA

House dust mite sensitization, eczema, and wheeze increase risk of shellfish sensitization

Non peer reviewe

Associations between caesarean delivery and allergic outcomes: Results from the GUSTO study

10.1016/j.anai.2017.02.021Annals of Allergy, Asthma and Immunology1185636-638GUSTO (Growing up towards Healthy Outcomes

Relation of infant dietary patterns to allergic outcomes in early childhood

10.1111/pai.12727Pediatric Allergy and Immunology285490-495GUSTO (Growing up towards Healthy Outcomes

Maternal PUFA status and offspring allergic diseases up to the age of 18 months

10.1017/S000711451500001XBritish Journal of Nutrition1136975-983GUSTO (Growing up towards Healthy Outcomes

Toward personalization of asthma treatment according to trigger factors

International audienceAsthma is a severe and chronic disabling disease affecting more than 300 million people worldwide. Although in the past few drugs for the treatment of asthma were available, new treatment options are currently emerging, which appear to be highly effective in certain subgroups of patients. Accordingly, there is a need for biomarkers that allow selection of patients for refined and personalized treatment strategies. Recently, serological chip tests based on microarrayed allergen molecules and peptides derived from the most common rhinovirus strains have been developed, which may discriminate 2 of the most common forms of asthma, that is, allergen- and virus-triggered asthma. In this perspective, we argue that classification of patients with asthma according to these common trigger factors may open new possibilities for personalized management of asthma